newsfilter
← Latest News
GlobeNewswire·

Cellectis Announces Arbitral Decision in Dispute with Servier

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,